Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495012 | 1.00 | HIF1A (0.40) | HIF1AHDAC1FFAR1PPARACES1 | |
| SCHEMBL4493369 | 0.91 | CES1 (0.39) | HDAC1CES1RXFP1KDM4EMAPT | |
| SCHEMBL4493365 | 0.91 | CES1 (0.39) | HDAC1CES1RXFP1KDM4EMAPT | |
| SCHEMBL4496723 | 0.89 | CES1 (0.47) | CES1RXFP1MAPT | |
| SCHEMBL4496719 | 0.89 | CES1 (0.47) | CES1RXFP1MAPT | |
| SCHEMBL4507715 | 0.88 | CES1 (0.46) | CES1RXFP1KDM4EMAPT | |
| SCHEMBL4507721 | 0.88 | CES1 (0.46) | CES1RXFP1KDM4EMAPT | |
| SCHEMBL4491987 | 0.87 | CES1 (0.36) | CES1RXFP1KDM4EMAPT | |
| SCHEMBL4491989 | 0.87 | CES1 (0.36) | CES1RXFP1KDM4EMAPT | |
| SCHEMBL4495110 | 0.86 | HDAC1 (0.39) | HDAC1CES1RXFP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | HIF1A 1968/4885HDAC1 3369/4885FFAR1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.